Hypoparathyroidism screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Hypoparathyroidism}} | {{Hypoparathyroidism}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{Anmol}} | ||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend routine screening for hypoparathyroidism. However, a significant number of patients of isolated idiopathic hypoparathyroidism with hypercaliuria may have a de novo calcium-sensing receptor (CASR) gene mutation | There is insufficient evidence to recommend routine screening for hypoparathyroidism. However, a significant number of patients of isolated idiopathic hypoparathyroidism with hypercaliuria may have a de novo calcium-sensing receptor (CASR) gene mutation. Molecular screening of CASR gene in patients with this presentation is recommended during initial work-up as it has potentially important clinical relevance to the patient’s prognosis. | ||
==Screening== | ==Screening== | ||
There is insufficient evidence to recommend routine screening for hypoparathyroidism. However, a significant number of patients of isolated idiopathic hypoparathyroidism with | *There is insufficient evidence to recommend routine screening for hypoparathyroidism. | ||
*However, a significant number of patients of isolated idiopathic hypoparathyroidism with hypercalciuria may have a de novo calcium-sensing receptor (CASR) gene mutation. | |||
*All patients require treatment with 1-hydroxylated vitamin D3 for correction of hypocalcemia. | |||
*As 1-hydroxylated vitamin D3 may precipitate prolonged episode of hypercalciuria, the treatment decision should be evaluated on an individual basis in asymptomatic or mildly symptomatic patients. | |||
*Molecular screening of CASR gene in patients with isolated idiopathic hypoparathyroidism with hypercaliuria is recommended during initial work-up as it has potentially important clinical relevance to the patient’s prognosis.<ref name="pmid11701698">{{cite journal |vauthors=Lienhardt A, Bai M, Lagarde JP, Rigaud M, Zhang Z, Jiang Y, Kottler ML, Brown EM, Garabédian M |title=Activating mutations of the calcium-sensing receptor: management of hypocalcemia |journal=J. Clin. Endocrinol. Metab. |volume=86 |issue=11 |pages=5313–23 |year=2001 |pmid=11701698 |doi=10.1210/jcem.86.11.8016 |url=}}</ref> | |||
==References== | ==References== | ||
Revision as of 20:08, 21 September 2017
|
Hypoparathyroidism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypoparathyroidism screening On the Web |
|
American Roentgen Ray Society Images of Hypoparathyroidism screening |
|
Risk calculators and risk factors for Hypoparathyroidism screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
There is insufficient evidence to recommend routine screening for hypoparathyroidism. However, a significant number of patients of isolated idiopathic hypoparathyroidism with hypercaliuria may have a de novo calcium-sensing receptor (CASR) gene mutation. Molecular screening of CASR gene in patients with this presentation is recommended during initial work-up as it has potentially important clinical relevance to the patient’s prognosis.
Screening
- There is insufficient evidence to recommend routine screening for hypoparathyroidism.
- However, a significant number of patients of isolated idiopathic hypoparathyroidism with hypercalciuria may have a de novo calcium-sensing receptor (CASR) gene mutation.
- All patients require treatment with 1-hydroxylated vitamin D3 for correction of hypocalcemia.
- As 1-hydroxylated vitamin D3 may precipitate prolonged episode of hypercalciuria, the treatment decision should be evaluated on an individual basis in asymptomatic or mildly symptomatic patients.
- Molecular screening of CASR gene in patients with isolated idiopathic hypoparathyroidism with hypercaliuria is recommended during initial work-up as it has potentially important clinical relevance to the patient’s prognosis.[1]
References
- ↑ Lienhardt A, Bai M, Lagarde JP, Rigaud M, Zhang Z, Jiang Y, Kottler ML, Brown EM, Garabédian M (2001). "Activating mutations of the calcium-sensing receptor: management of hypocalcemia". J. Clin. Endocrinol. Metab. 86 (11): 5313–23. doi:10.1210/jcem.86.11.8016. PMID 11701698.